Letter to the Editor

You have full text access to this OnlineOpen article

The value of routine BMD monitoring after starting bisphosphonate treatment

  1. Katy JL Bell1,*,
  2. Andrew Hayen1,
  3. Les Irwig1,
  4. Petra Macaskill1,
  5. Jonathan C Craig1,2,
  6. Kristine E Ensrud3,
  7. Douglas C Bauer4

Article first published online: 18 DEC 2009

DOI: 10.1359/jbmr.091111

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 173–174, January 2010

Additional Information

How to Cite

Bell, K. J., Hayen, A., Irwig, L., Macaskill, P., Craig, J. C., Ensrud, K. E. and Bauer, D. C. (2010), The value of routine BMD monitoring after starting bisphosphonate treatment. J Bone Miner Res, 25: 173–174. doi: 10.1359/jbmr.091111

Author Information

  1. 1

    School of Public Health, The University of Sydney, New South Wales, Australia

  2. 2

    Department of Nehprology, Children's Hospital at Westmead, New South Wales, Australia

  3. 3

    University of Minnesota Medical School, Veterans Affairs Medical Center, Minneapolis, MN, USA

  4. 4

    University of California–San Francisco, San Francisco, CA, USA

*School of Public Health, The University of Sydney, Screening and Test Evaluation Program (STEP), Edward Ford Building (A27), New South Wales, 2006 Australia.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 18 DEC 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (43K)

References

  • 1
    Bell KJL, Hayen A, Macaskill P, Irwig L, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009; 338: b2266.
  • 2
    Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009; 24: 1643–1646.
    Direct Link:
  • 3
    Chapurlat RD, Palermo L, Ramsay P, Cummings S. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005; 16: 842–848.
  • 4
    Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int. (in press), 2009; (DOI 10.1007/s00198-009-0991-1).
  • 5
    Cummings S, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA. 2000; 283: 1318–1321.
  • 6
    Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient compliance. Hypertension. 1980; 2: 757–764.
  • 7
    National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 160: alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. 2008 (cited October 2009); available from: www.nice.org.uk/nicemedia/pdf/TA160guidance.pdf.
  • 8
    The Australian Government, Department of Health and Ageing. Risedronate sodium, tablet, 5 mg, (Actonel) and 35 mg (Actonel Once-a-week), Risedronate sodium and Calcium carbonate, pack containing 4 tablets risedronate sodium, 35 mg, and 24 tablets calcium carbonate, 1.25 g (equivalent to 500 mg calcium) (Actonel Combi). 2008 (cited October 2009); available from: www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-risedronate-july08.
  • 9
    Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Mixed models showed no need for initial response monitoring after starting anti-hypertensive therapy. J Clin Epidemiol. 2009; 62: 650–659.
  • 10
    Bell KJL, Irwig L, Craig JC, Macaskill P. Use of randomized trials to decide when to monitor response to new treatment. BMJ. 2008; 336: 361–365.
  • 11
    Irwig L, Glasziou PP. Choosing the best monitoring tests. In: GlasziouPP, IrwigL, AronsonJK, eds. Evidence-Based Medical Monitoring: From Principles to Practice. London: Blackwell Publishing, BMJ Books; 2008: 63–74.
  • 12
    Bland JM, Altman DG. Measurement error. BMJ. 1996; 313: 744.
View Full Article (HTML) Get PDF (43K)